Select Publications

Book Chapters

Day RO; Williams KM; Graham GG, 2013, 'Urate-lowering therapy: Uricosurics', in Gout, pp. 174 - 189, http://dx.doi.org/10.2217/EBO.13.104

Day RO; Graham GG; Williams KM, 2013, 'Propionic acid derivative drugs (Profens)', in Encyclopedia of Inflammatory Diseases, Springer-Verlag, Berlin Heidelberg, http://www.springerreference.com/

Bachmeier CJ; Brooks PM; Day RO; Graham GG; Littlejohn GO; Morand E; Pile K; Williams KM, 2005, 'Disease-modifying anti-rheumatic drugs (DMARD)', in Nijkamp FJ; Parnham MJ (ed.), Principles of Immunopharmacology (2nd Ed), edn. 2nd, Birkhauser Verlag, Basel, pp. 511 - 544

Day RO; Quinn DI; March LM; Graham GG; Williams KM, 2000, 'Rheumatoid arthritis. New Frontiers in pathogenesis and treatment', in NSAIDs and analgesics, edn. Original, Oxford University Press, Oxford, England, pp. 307 - 328

Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1999, 'Disease-modifying antirheumatic drugs', in Nijkamp FP; Parnham MJ (ed.), Principles of Immunopharmacology, edn. 3, Birkhauser Verlag (Springer), Basel, Switzerland, pp. 379 - 403

Graham GG; Milligan MK; Day RO; Williams KM; Ziegler JB, 1998, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in Rainsford KD; Powanda MC (ed.), SAFETY AND EFFICACY OF NON-PRESCRIPTION (OTC) ANALGESICS AND NSAIDS, Kluwer Academic Publishers, Dordrecht, pp. 77 - 92, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000081416000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

Bachmeier CJ; Handel ML; Conaghan PG; Williams KM; Graham GG; Brooks PM; Day RO, 1998, 'Disease Modifying antirheumatic drugs', in Current Opinion in Rheumatology, edn. 3, Burkhauser, Basel, Switzerland, pp. 183 - 190, http://dx.doi.org/10.1097/00002281-199705000-00003

Graham GG; Milligan MK; Day RO; Williams KM; Zeig , 1997, 'Therapeutic considerations from pharmacokinetics and metabolism: ibuprofen and paracetamol', in In: `Safety and efficacy of non-prescription (OTC) analgesics, edn. Original, Kluwer Academic Publishers, Great Britain, pp. 77 - 92

Vesey G; Ashbolt NJ; Wallner G; Dorsch R; Williams KM; Veal DA, 1995, 'Assessing cryptosporidium parvum oocyst viability with fluorescent in situ hybridization using ribosomal RNA probes and flow cytometry', in Protozoan parasites and water, edn. Original, Royal Society of Chemistry, Cambridge, pp. 133 - 138

Journal articles

Day RO; Lau W; Stocker SL; Aung E; Coleshill MJ; Schulz M; Bechara J; Carland JE; Graham GG; Williams KM; McLachlan AJ, 2019, 'Management of gout in older people', Journal of Pharmacy Practice and Research, vol. 49, pp. 90 - 97, http://dx.doi.org/10.1002/jppr.1511

Kumar SS; McManus H; Radovich T; Greenfield JR; Viardot A; Williams KM; Cronin P; Day RO, 2018, 'Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM)', European Journal of Clinical Pharmacology, vol. 74, pp. 1327 - 1332, http://dx.doi.org/10.1007/s00228-018-2506-5

Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KJ; Portek I; Williams KM; Westbrook JI, 2017, 'Effectiveness of an electronic patient-centred self-management tool for gout sufferers: A cluster randomised controlled trail protocol', BMJ Open, vol. 7, http://dx.doi.org/10.1136/bmjopen-2017-017281

Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO, 2017, 'Individualising the dose of allopurinol in patients with gout', British Journal of Clinical Pharmacology, vol. 83, pp. 2015 - 2026, http://dx.doi.org/10.1111/bcp.13307

Duong JK; Kroonen MYAM; Kumar SS; Heerspink HL; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2017, 'A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function', European Journal of Clinical Pharmacology, vol. 73, pp. 981 - 990, http://dx.doi.org/10.1007/s00228-017-2251-1

Day RO; Kannangara DRW; Stocker SL; Carland JE; Williams KM; Graham GG, 2017, 'Allopurinol: insights from studies of dose–response relationships', Expert Opinion on Drug Metabolism and Toxicology, vol. 13, pp. 449 - 462, http://dx.doi.org/10.1080/17425255.2017.1269745

Kamel B; Graham GG; Williams KM; Pile KD; Day RO, 2017, 'Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat', Clinical Pharmacokinetics, vol. 56, pp. 459 - 475, http://dx.doi.org/10.1007/s40262-016-0466-4

Day RO; Kamel B; Kannangara DRW; Williams KM; Graham GG, 2016, 'Xanthine oxidoreductase and its inhibitors: Relevance for gout', Clinical Science, vol. 130, pp. 2167 - 2180, http://dx.doi.org/10.1042/CS20160010

Vaccher S; Kannangara DRW; Baysari MT; Reath J; Zwar N; Williams KM; Day RO, 2016, 'Barriers to care in gout: From prescriber to patient', Journal of Rheumatology, vol. 43, pp. 144 - 149, http://dx.doi.org/10.3899/jrheum.150607

Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, vol. 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984

Smith FC; Kumar SS; Furlong TJ; Gangaram SV; Greenfield JR; Stocker SL; Graham GG; Williams KM; Day RO, 2016, 'Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration', American Journal of Kidney Diseases, vol. 68, pp. 990 - 992, http://dx.doi.org/10.1053/j.ajkd.2016.08.017

Moon J; Kumar SS; Graham GG; Baysari MT; Williams KM; Chen W; Viardot A; Greenfield JR; Day RO, 2016, 'Trends in metformin utilisation and dose appropriateness in Australia', European Journal of Clinical Pharmacology, vol. 72, pp. 1489 - 1496, http://dx.doi.org/10.1007/s00228-016-2117-y

Rasheed H; McKinney C; Stamp LK; Dalbeth N; Topless RK; Day R; Kannangara D; Williams K; Smith M; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; Lu L; Stahl EA; Choi HK; So A; Merriman TR, 2016, 'The toll-like receptor 4 (TLR4) variant rs2149356 and risk of gout in European and polynesian sample sets', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0147939

Kannangara DRW; Phipps-Green AJ; Dalbeth N; Stamp LK; Williams KM; Graham GG; Day RO; Merriman TR, 2016, 'Hyperuricaemia: Contributions of urate transporter ABCG2 and the fractional renal clearance of urate', Annals of the Rheumatic Diseases, vol. 75, pp. 1363 - 1366, http://dx.doi.org/10.1136/annrheumdis-2015-208111

Kannangara DRW; Graham GG; Williams KM; Day RO, 2016, 'Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine', Clinical Rheumatology, vol. 35, pp. 2375 - 2376, http://dx.doi.org/10.1007/s10067-015-3165-x

Hmar RC; Kannangara DRW; Ramasamy SN; Baysari MT; Williams KM; Day RO, 2015, 'Understanding and improving the use of allopurinol in a teaching hospital', Internal Medicine Journal, vol. 45, pp. 383 - 390, http://dx.doi.org/10.1111/imj.12701

Merriman TR; Stamp LK; Dalbeth N; Topless R; Day R; Kannangara D; Williams K; Janssen M; Jansen T; Joosten LA; Radstake T; Riches PL; Tausche A-K; Liote F; So A; McKinney C, 2015, 'Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout', ARTHRITIS & RHEUMATOLOGY, vol. 67, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000370860204715&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a

McKinney C; Stamp LK; Dalbeth N; Topless RK; Day RO; Kannangara DRW; Williams KM; Janssen M; Jansen TL; Joosten LA; Radstake TR; Riches PL; Tausche AK; Lioté F; So A; Merriman TR, 2015, 'Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout', Arthritis Research and Therapy, vol. 17, http://dx.doi.org/10.1186/s13075-015-0802-3

Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO, 2015, 'The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus', British Journal of Clinical Pharmacology, vol. 79, pp. 617 - 623, http://dx.doi.org/10.1111/bcp.12525

Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MHH; Williams KM; Tian YC; Juan KC; Wu YJJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI, 2015, 'Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: The impact of renal insufficiency, high plasma levels of oxypurinol and granulysin', Annals of the Rheumatic Diseases, vol. 74, pp. 2157 - 2164, http://dx.doi.org/10.1136/annrheumdis-2014-205577

Kannangara DRW; Graham GG; Williams KM; Day RO, 2014, 'Hypouricemic effects of prednisone and allopurinol: An uneven playing field?', Canadian Journal of Cardiology, vol. 30, pp. 376.e1, http://dx.doi.org/10.1016/j.cjca.2013.04.015

Ghosh D; Williams KM; Graham GG; Nair P; Buscher H; Day RO, 2014, 'Multiple episodes of aspirin overdose in an individual patient: A case report', Journal of Medical Case Reports, vol. 8, pp. 1 - 5, http://dx.doi.org/10.1186/1752-1947-8-374

Rasheed H; Topless R; Day R; Kannangara D; Williams K; Bradbury L; Brown M; Hill C; Lester S; Rischmueller M; Smith M; Andres M; Bardin T; Doherty M; Janssen M; Jansen T; Joosten L; Perez-Ruiz F; Radstake T; Riches PL; Roddy E; Tausche A-K; Stamp LK; Dalbeth N; Liote F; So A; McKinney C; Merriman TR, 2014, 'Association of the Toll-like Receptor 4 (TLR4) Gene with Gout.', ARTHRITIS & RHEUMATOLOGY, vol. 66, pp. S1294 - S1295, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344384906196&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kannangara DRW; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO, 2013, 'An audit of a therapeutic drug monitoring service for allopurinol therapy', Therapeutic Drug Monitoring, vol. 35, pp. 863 - 866, http://dx.doi.org/10.1097/FTD.0b013e318299920a

Ramasamy SN; Korb-Wells CS; Kannangara DRW; Smith MWH; Wang N; Roberts DM; Graham GG; Williams KM; Day RO, 2013, 'Allopurinol hypersensitivity: A systematic review of all published cases, 1950-2012', Drug Safety, vol. 36, pp. 953 - 980, http://dx.doi.org/10.1007/s40264-013-0084-0

Day R; Lee H; Graham G; Williams K, 2013, 'Benzbromarone: Availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt on benzbromarone)', New Zealand Medical Journal, vol. 126, pp. 124 - 126

Brett J; Chong O; Graham GG; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Antifungal Use and Therapeutic Monitoring of Plasma Concentrations of Itraconazole in Heart and Lung Transplantation Patients.', Therapeutic Drug Monitoring, vol. 35, pp. 133 - 136, http://dx.doi.org/10.1097/FTD.0b013e318275fe69

Lee M-H; Stocker S; Williams KM; Day RO, 2013, 'HLA-B*5801 should be used to screen for risk of Stevens-Johnson Syndrome (SJS) in family members of Han-Chinese patients commencing allopurinol therapy', Journal of Rheumatology, vol. 40, pp. 96 - 97, http://dx.doi.org/10.3899/jrheum.120803

Wong C; Kumar SS; Graham GG; Begg EJ; Chin P; Brett J; Ray J; Marriott D; Williams KM; Day RO, 2013, 'Comparing dose prediction software used to manage gentamicin dosing', Internal Medicine Journal, vol. 43, pp. 519 - 525, http://dx.doi.org/10.1111/imj.12067

Stocker S; Mclachlan AJ; Savic RM; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'The pharmacokinetics of oxypurinol in people with gout', British Journal of Clinical Pharacology, vol. 74, pp. 477 - 489, http://dx.doi.org/10.1111/j.1365-2125.2012.04207.x

Kannangara D; Roberts DM; Furlong TJ; Graham GG; Williams K; Day RO, 2012, 'Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease', British Journal of Clinical Pharmacology, vol. 73, pp. 828 - 829, http://dx.doi.org/10.1111/j.1365-2125.2011.04147.x

Kannangara DRW; Ramasamy SN; Indraratna P; Stocker S; Graham GG; Jones G; Portek I; Williams KM; Day RO, 2012, 'Fractional clearance of urate: Validation of measurement in spot urine samples in healthy subjects and gouty patients', Arthritis Research and Therapy, vol. 14, pp. R189 - R197, http://dx.doi.org/10.1186/ar4020

Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO, 2012, 'Metformin therapy in patients with chronic kidney disease', Diabetes Obesity and Metabolism, vol. 14, pp. 963 - 965, http://dx.doi.org/10.1111/j.1463-1326.2012.01617.x

Lee M-H; Stocker S; Anderson JM; Phillips EJ; Nolan DL; Williams KM; Graham GG; Sullivan JR; Day RO, 2012, 'Initiating allopurinol therapy: Do we need to know the patient's human leucocyte antigen status?', Internal Medicine Journal, vol. 42, pp. 411 - 416, http://dx.doi.org/10.1111/j.1445-5994.2011.02567.x

Milder T; Williams K; Ritchie JE; Lipworth WL; Day RO, 2011, 'Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: Engagement with information and perceptions of risk', Age and Ageing, vol. 40, pp. 254 - 259, http://dx.doi.org/10.1093/ageing/afq160

Milder T; Lipworth WL; Williams KM; Ritchie JE; Day RO, 2011, '"It looks after me": how older patients make decisions about analgesics for osteoarthritis.', Arthritis Care and Research, vol. 63, pp. 1280 - 1286, http://dx.doi.org/10.1002/acr.20514

Stocker SL; Graham GG; McLachlan AJ; Williams K; Day RO, 2011, 'Pharmacokinetic and Pharmacodynamic interaction between allopurinol and probenecid in patients with gout', Journal of Rheumatology, vol. 38, pp. 904 - 910, http://dx.doi.org/10.3899/jrheum.101160

Ng DY; Stocker SL; Graham GG; Williams KM; Day RO, 2011, 'Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers', European Journal of Clinical Pharmacology, vol. 67, pp. 709 - 713, http://dx.doi.org/10.1007/s00228-010-0963-6

Graham GG; Punt J; Manit A; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup L; Carl m kirkpatrick CM; Ray J; Timmins P; Williams KM, 2011, 'Clinical pharmacokinetics of metforim', Clinical Pharmacokinetics, vol. 50, pp. 81 - 98, http://dx.doi.org/10.2165/11534750-000000000-00000

Wang N; Lipworth WL; Ritchie JE; Williams K; Day RO, 2011, 'Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines', Internal Medicine Journal, vol. 41, pp. 314 - 320, http://dx.doi.org/10.1111/j.1445-5994.2010.02239.x

Day RO; Liauw WS; Tozer L; McElduff P; Beckett RJ; Williams K, 2010, 'A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenpausal women', BMC Research Notes, vol. 3, pp. 1 - 8, http://dx.doi.org/10.1186/1756-0500-3-180


Back to profile page